The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation

Samantha Brunt, S. Lee, Lloyd D'Orsogna, Christine Bundell, Sally Burrows, Patricia Price

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    © 2014 Samantha J. Brunt et al. Objectives. Elevated humoral responses to cytomegalovirus (CMV) associate with increased risk of cardiovascular disease (CVD) in HIV patients on antiretroviral therapy (ART). To better understand the persistence of CMV humoral responses in relation to CVD, we determined trends in CMV antibody levels over the first 10 years on ART. Design. We describe longitudinal analyses of plasma from 13 HIV patients commencing ART with
    Original languageEnglish
    Article number 947432
    Pages (from-to)1-8
    Number of pages8
    JournalDisease Markers
    Volume2014
    DOIs
    Publication statusPublished - 23 Nov 2014

    Fingerprint

    Dive into the research topics of 'The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation'. Together they form a unique fingerprint.

    Cite this